StockDrifts LogoStockDrifts

cytogen 217330

Company
싸이토젠cytogen
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2026-06-23

cytogen (217330) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for cytogen is dated 2025-11-05; the most recent is 2026-06-23.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-08-31BUY증여취소
전병희
Jeon Byeong-hee
Internal director750.0K₩3,145-4.1%₩2.4B ($1.6M)
2026-06-23SELL증여
전병희
Jeon Byeong-hee
Internal director-750.0K---
2026-02-24SELL시간외매매
전병희
Jeon Byeong-hee
Internal director-1.3M---
2025-11-05BUY자사주상여금
정윤영
Yunyoung Jeong
Managing Director2.0K₩2,975+108.7%₩6M ($4K)

Frequently asked questions

Who has been buying cytogen stock?
0 distinct insiders have filed 0 disclosed insider purchases in cytogen (217330), most recently on 2026-06-23. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does cytogen have?
cytogen has 0 buy-side and 0 sell-side disclosures on record, spanning 2025-11-05 to 2026-06-23.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.